Allergy, Asthma & Clinical Immunology (Aug 2023)

CMV retinitis in patients on mycophenolate immunosuppression: a report of two cases

  • Prem N. Patel,
  • Ahmed M. Alkaliby,
  • Mitul C. Mehta,
  • Angeline L. Wang

DOI
https://doi.org/10.1186/s13223-023-00817-z
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background The rate of cytomegalovirus (CMV) retinitis is increasing, likely secondary to aggressive immunosuppressive regimens for a variety of diseases. Transplant and rheumatological literature show growing evidence suggesting a unique relationship between CMV infection and mycophenolate in particular. This study reports two cases of CMV retinitis infection in patients on mycophenolate immunosuppression. Case presentation Case A was a 39-year-old African American woman with systemic lupus erythematosus (SLE) with stage IV lupus nephritis who presented for bilateral retinal detachments with areas of moth-eaten and thin retina concerning for prior viral retinitis. Case B was a 53-year-old man who presented with floaters in the right eye status-post heart transplant since 2008 on immunosuppressive therapy. Fundoscopic examination of the right eye showed frosted branch angiitis with intraretinal hemorrhage and inner retinal thickening and disorganization, consistent with CMV retinitis infection. Both patients were on mycophenolate immunosuppression with the recommendation to reduce or discontinue mycophenolate. Conclusion Patients on mycophenolate immunosuppression may be more vulnerable to cytomegalovirus infection, including CMV retinitis. Ophthalmologists should be aware of this increased risk and consider reducing or discontinuing mycophenolate to promote viral clearance in these susceptible patients, in conjunction with the patient’s transplant or rheumatology teams.

Keywords